Global Growth Hormone Deficiency (GHD) Market 2022-2028

Global Growth Hormone Deficiency (GHD) Market 2022-2028

According to market research study published by Gen Consulting Company, the global growth hormone deficiency market is expected to reach approximately USD 4,661 million, representing a CAGR of 4.4% during the forecast period 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global growth hormone deficiency market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the growth hormone deficiency industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the brand, route of administration, distribution channel, application, and region. The global market for growth hormone deficiency can be segmented by brand: Genotropin, Humatrope, Norditropin, Omnitrope, Saizen, others. Growth hormone deficiency market is further segmented by route of administration: intramuscular, intravenous, subcutaneous. Based on distribution channel, the growth hormone deficiency market is segmented into: e-commerce, hospital & clinics, pharmacies & drug stores. On the basis of application, the growth hormone deficiency market also can be divided into: adult growth hormone deficiency (AGHD), idiopathic short stature (ISS), pediatric growth hormone deficiency, Prader-Willi syndrome (PWS), small for gestational age (SGA), turner syndrome (TS), others. Growth hormone deficiency market by region is categorized into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By brand:

• Genotropin
• Humatrope
• Norditropin
• Omnitrope
• Saizen
• others

By route of administration:

• intramuscular
• intravenous
• subcutaneous

By distribution channel:

• e-commerce
• hospital & clinics
• pharmacies & drug stores

By application:

• adult growth hormone deficiency (AGHD)
• idiopathic short stature (ISS)
• pediatric growth hormone deficiency
• Prader-Willi syndrome (PWS)
• small for gestational age (SGA)
• turner syndrome (TS)
• others

By region:

• North America
• Asia Pacific
• Europe
• Rest of the World (ROW)

The report has also analysed the competitive landscape of the global growth hormone deficiency market with some of the key players being Anhui Anke Biotechnology (Group) Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring B.V., Ipsen S.A., Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global growth hormone deficiency market.
• To classify and forecast the global growth hormone deficiency market based on brand, route of administration, distribution channel, application, region.
• To identify drivers and challenges for the global growth hormone deficiency market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global growth hormone deficiency market.
• To identify and analyze the profile of leading players operating in the global growth hormone deficiency market.

Why Choose This Report

• Gain a reliable outlook of the global growth hormone deficiency market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.